B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVD
The B-specific consortium aims to identify and target specific B-cell subsets to develop personalized therapies for atherosclerosis and improve cardiovascular disease risk assessment and management.
Projectdetails
Introduction
Atherosclerosis is the major underlying condition of cardiovascular disease (CVD) and one of the leading causes of mortality. Rupture or erosion of atherosclerotic lesions can lead to acute cardiovascular events, such as myocardial infarction and stroke. This makes biomarkers to diagnose patients at risk for these events and develop tailored preventive interventions an urgent need.
Background
Although atherosclerosis is a chronic inflammatory disease, clinical investigation of the adaptive immune system as a potential rheostat for disease development has been limited.
Objectives
The B-specific consortium aims to classify and mitigate the risk of CVD by:
- Generating novel types of genetic data.
- Defining novel prognostic and therapeutic targets attained from our recent discovery of a specific B-cell subset.
Methodology
We will employ state-of-the-art technology, including:
- Single cell RNA sequencing
- BCR repertoire analysis
- Mass spectrometry-based identification of autoantigens in CVD patient material
With access to large population-based cohorts (FIMCOD, ERGO Study) spanning healthy adults of 40-105 years of age, we aim to:
- Assess the prognostic value of circulating B cell subsets and antibodies in (sub)clinical atherosclerosis.
- Investigate the contribution of genetic disposition.
Analysis
Using the extensive genomics data of the ERGO Study, we will be able to determine causal links between the prognostic indicators and disease progression by applying Mendelian Randomization experiments. We will confirm these relationships in ex vivo and in vivo models of atherosclerosis.
Expected Outcomes
Based on these findings, B-specific aims to develop at least one proof-of-concept therapy targeting specific B cells.
Dissemination
B-specific will implement an active open science platform. In combination with a targeted dissemination approach to healthcare professionals, we aim to impact cardiology practice and provide important new means of patient stratification and treatment options.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 4.006.599 |
Totale projectbegroting | € 4.006.599 |
Tijdlijn
Startdatum | 1-10-2023 |
Einddatum | 30-9-2027 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT LEIDENpenvoerder
- LUNDS UNIVERSITET
- KATHOLIEKE UNIVERSITEIT LEUVEN
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- INNOVATION ACTA SRL
- HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEaseThe MIRACLE project aims to develop advanced multiomics-based risk prediction models for atherosclerotic cardiovascular disease by integrating genetic data and biomarkers for improved early diagnosis and treatment. | EIC Pathfinder | € 4.000.000 | 2023 | Details |
Human Antibody-enabled Cardiovascular Personalized TheranosisABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients. | EIC Pathfinder | € 3.639.665 | 2024 | Details |
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatmentThe project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies. | EIC Pathfinder | € 3.740.868 | 2023 | Details |
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial InfarctionTargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation. | EIC Pathfinder | € 3.999.840 | 2023 | Details |
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair InterventionsCARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes. | EIC Pathfinder | € 4.349.410 | 2023 | Details |
MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase
The MIRACLE project aims to develop advanced multiomics-based risk prediction models for atherosclerotic cardiovascular disease by integrating genetic data and biomarkers for improved early diagnosis and treatment.
Human Antibody-enabled Cardiovascular Personalized Theranosis
ABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients.
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment
The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction
TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions
CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
The function of B cells in myocardial infarction-accelerated atherosclerosisThis project aims to investigate glucocorticoid signaling in B cells post-myocardial infarction to identify therapeutic targets for preventing accelerated atherosclerosis in cardiovascular disease. | ERC Starting... | € 1.475.638 | 2023 | Details |
Single cEll guided polygeniC Risk prEdicTion of ASCVDThis project aims to develop innovative polygenic risk models for atherosclerotic cardiovascular disease by leveraging genetic data and mechanistic insights to improve risk prediction and prevention. | ERC Consolid... | € 2.000.000 | 2024 | Details |
The extracellular matrix as a mediator of cell-cell communication in cardiovascular inflammationThe project aims to explore the extracellular matrix proteome in atherosclerosis and myocardial infarction to identify novel therapeutic targets for individualized treatment strategies. | ERC Starting... | € 1.495.750 | 2023 | Details |
Moving from whole genome cfDNA methylation to a PCR-based liquid biopsy assay for detecting high-risk atherosclerotic plaquesThe U-BiomarCARE project aims to develop a PCR-based method to detect plaque-specific DNA methylation in plasma, enabling timely diagnosis of coronary artery disease in both men and women. | ERC Proof of... | € 150.000 | 2023 | Details |
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profilesProtego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications. | ERC Starting... | € 1.498.295 | 2024 | Details |
The function of B cells in myocardial infarction-accelerated atherosclerosis
This project aims to investigate glucocorticoid signaling in B cells post-myocardial infarction to identify therapeutic targets for preventing accelerated atherosclerosis in cardiovascular disease.
Single cEll guided polygeniC Risk prEdicTion of ASCVD
This project aims to develop innovative polygenic risk models for atherosclerotic cardiovascular disease by leveraging genetic data and mechanistic insights to improve risk prediction and prevention.
The extracellular matrix as a mediator of cell-cell communication in cardiovascular inflammation
The project aims to explore the extracellular matrix proteome in atherosclerosis and myocardial infarction to identify novel therapeutic targets for individualized treatment strategies.
Moving from whole genome cfDNA methylation to a PCR-based liquid biopsy assay for detecting high-risk atherosclerotic plaques
The U-BiomarCARE project aims to develop a PCR-based method to detect plaque-specific DNA methylation in plasma, enabling timely diagnosis of coronary artery disease in both men and women.
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles
Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.